Kiran Girdhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kiran Girdhar has a total of 309 co-authors. Here are the top co-authors by number of shared publications:
- Panos Roussos
Icahn School of Medicine at Mount Sinai
29 shared publications - Gabriel E. Hoffman
Icahn School of Medicine at Mount Sinai
26 shared publications - John F. Fullard
Icahn School of Medicine at Mount Sinai
24 shared publications - Jaroslav Bendl
Icahn School of Medicine at Mount Sinai
23 shared publications - Georgios Voloudakis
Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, USA
20 shared publications - Vahram Haroutunian
Mount Sinai and JJ Peters VA Medical Center
16 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Research Square
Cell-type-resolved mRNA 3′-end remodeling in Alzheimer’s disease
Alternative polyadenylation diversifies messenger RNAs by altering coding sequences and 3′ untranslated regions, but its organization across human brain cell types and disruption in neurodegeneration remain poorly understood. By analyzing 3′-capture single-nucleus RNA sequencing data of 6.3 million nuclei from the prefrontal cortex of 1,494 human donors, we defined 108,768 polyadenylation sites across 25,274 genes, most of which were absent from the GENCODE polyadenylation-site annotation. Polyadenylation-site usage was strongly cell-type-specific and revealed regulatory differences not captured by gene expression. With increasing Alzheimer’s disease clinicopathological severity, excitatory neurons, oligodendrocytes and immune cells showed increased distal-site preference, including reduced relative usage of intronic sites and increased distal 3′ untranslated region usage in synaptic and RNA-processing genes. External single-nucleus data supported neuronal and oligodendrocyte patterns, while complementary analyses of purified microglia supported selected immune-cell findings. Integrative analyses of cleavage and polyadenylation factor expression, co-regulated usage networks, sequence motifs and published perturbations prioritized the cleavage factor Im complex as a candidate regulator. These findings identify cell-type-specific messenger RNA 3′-end remodeling as a reproducible dimension of Alzheimer’s disease molecular pathology that is only partly captured by gene-level analyses.
- 7 October 2026
- Published by Springer Nature in Research Square
Open AccessCell-type-resolved mRNA 3′-end remodeling in Alzheimer’s disease
Alternative polyadenylation diversifies messenger RNAs by altering coding sequences and 3′ untranslated regions, but its organization across human brain cell types and disruption in neurodegeneration remain poorly understood. By analyzing 3′-capture single-nucleus RNA sequencing data of 6.3 million nuclei from the prefrontal cortex of 1,494 human donors, we defined 108,768 polyadenylation sites across 25,274 genes, most of which were absent from the GENCODE polyadenylation-site annotation. Polyadenylation-site usage was strongly cell-type-specific and revealed regulatory differences not captured by gene expression. With increasing Alzheimer’s disease clinicopathological severity, excitatory neurons, oligodendrocytes and immune cells showed increased distal-site preference, including reduced relative usage of intronic sites and increased distal 3′ untranslated region usage in synaptic and RNA-processing genes. External single-nucleus data supported neuronal and oligodendrocyte patterns, while complementary analyses of purified microglia supported selected immune-cell findings. Integrative analyses of cleavage and polyadenylation factor expression, co-regulated usage networks, sequence motifs and published perturbations prioritized the cleavage factor Im complex as a candidate regulator. These findings identify cell-type-specific messenger RNA 3′-end remodeling as a reproducible dimension of Alzheimer’s disease molecular pathology that is only partly captured by gene-level analyses.
- Open Access
- 23 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8133) , 1003-1015
Lifespan single-cell transcriptomic atlas of the human prefrontal cortex
The human brain undergoes profound changes from early development through late adulthood, shaping cognition, behaviour and vulnerability to disease1,2. Understanding how these changes are organized within specific brain regions and cell types is essential for interpreting normal ageing and its relationship to psychiatric and neurodegenerative disorders. The dorsolateral prefrontal cortex has a central role in higher cognitive functions and is particularly sensitive to age-related decline3, yet its cellular and molecular programs across the human lifespan remain poorly defined. Most existing studies4,5,6,7 have focused on restricted age ranges or disease-affected brains, limiting the ability to distinguish normative developmental and ageing trajectories from pathological processes. Consequently, a comprehensive, lifespan-resolved reference of cellular states in the human prefrontal cortex has been lacking. Here, using a single-nucleus transcriptomic atlas spanning the human lifespan, we show that the dorsolateral prefrontal cortex exhibits non-linear, cell-type-specific transcriptional trajectories characterized by dynamic remodelling during development, relative stability in midlife and selective molecular reactivation in late adulthood. We identify distinct neuronal and glial programs, including early-life neuronal resilience pathways and late-life glial programs associated with immune activation, stress responses and circadian reorganization. These programs are anatomically organized across cortical layers and grey–white matter domains, revealing coordinated spatial and molecular changes. Together, these findings provide a framework for understanding how cellular programs transition from resilience to vulnerability in the human cortex and establish a foundation for interpreting age-related cognitive decline and disease risk.
- 23 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8133) , 1003-1015
Open AccessLifespan single-cell transcriptomic atlas of the human prefrontal cortex
The human brain undergoes profound changes from early development through late adulthood, shaping cognition, behaviour and vulnerability to disease1,2. Understanding how these changes are organized within specific brain regions and cell types is essential for interpreting normal ageing and its relationship to psychiatric and neurodegenerative disorders. The dorsolateral prefrontal cortex has a central role in higher cognitive functions and is particularly sensitive to age-related decline3, yet its cellular and molecular programs across the human lifespan remain poorly defined. Most existing studies4,5,6,7 have focused on restricted age ranges or disease-affected brains, limiting the ability to distinguish normative developmental and ageing trajectories from pathological processes. Consequently, a comprehensive, lifespan-resolved reference of cellular states in the human prefrontal cortex has been lacking. Here, using a single-nucleus transcriptomic atlas spanning the human lifespan, we show that the dorsolateral prefrontal cortex exhibits non-linear, cell-type-specific transcriptional trajectories characterized by dynamic remodelling during development, relative stability in midlife and selective molecular reactivation in late adulthood. We identify distinct neuronal and glial programs, including early-life neuronal resilience pathways and late-life glial programs associated with immune activation, stress responses and circadian reorganization. These programs are anatomically organized across cortical layers and grey–white matter domains, revealing coordinated spatial and molecular changes. Together, these findings provide a framework for understanding how cellular programs transition from resilience to vulnerability in the human cortex and establish a foundation for interpreting age-related cognitive decline and disease risk.
- Top Cited PapersOpen Access
- 23 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8133) , 988-1002
Single-cell atlas of transcriptomic vulnerability across brain disorders
Neurodegenerative and neuropsychiatric diseases impose a considerable societal and public health burden. However, our understanding of the molecular mechanisms underlying these highly complex conditions remains limited 1,2 . Here, to gain deeper insights into the aetiology of different brain diseases, we used specimens from 1,494 unique donors to generate a population-scale single-cell transcriptomic atlas of the human dorsolateral prefrontal cortex, comprising over 6.3 million individual nuclei. The cohort includes neurotypical controls, as well as donors affected by eight common and complex brain disorders: Alzheimer’s disease (AD), diffuse Lewy body disease (DLBD), vascular dementia (Vas), Parkinson’s disease (PD), tauopathy, frontotemporal dementia, schizophrenia, and bipolar disorder. We show that interindividual variation accounts for a substantial portion of gene expression variation. By comparing transcriptomic variation across diseases, we reveal universal signatures enriched in basic cellular functions such as mRNA processing and protein localization. After discounting these cross-disease signatures, we show stronger genetic and transcriptomic concordance among AD, DLBD, Vas and PD. Furthermore, we characterize transcriptomic variation among different AD phenotypes, distinct from those observed in healthy ageing, revealing a reduction in neuronal abundance in individuals with more severe AD, coupled with an increase in immune and vascular cell populations. Exploring the neuropsychiatric symptoms (NPSs) that frequently accompany AD, we find an increased abundance of deep-layer excitatory neurons associated with a broad range of NPSs. By constructing transcriptome trajectories that capture AD progression, we implicate cell-type-specific responses in the early and late stages of AD. Our disease atlas provides a perspective of the transcriptomic landscape in neurodegenerative and neuropsychiatric disorders, shedding light on shared and distinct processes involving the neurological–immune–vascular systems, and identifying potential targets for therapeutic intervention.
- 23 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8133) , 988-1002
Top Cited PapersOpen AccessSingle-cell atlas of transcriptomic vulnerability across brain disorders
Neurodegenerative and neuropsychiatric diseases impose a considerable societal and public health burden. However, our understanding of the molecular mechanisms underlying these highly complex conditions remains limited 1,2 . Here, to gain deeper insights into the aetiology of different brain diseases, we used specimens from 1,494 unique donors to generate a population-scale single-cell transcriptomic atlas of the human dorsolateral prefrontal cortex, comprising over 6.3 million individual nuclei. The cohort includes neurotypical controls, as well as donors affected by eight common and complex brain disorders: Alzheimer’s disease (AD), diffuse Lewy body disease (DLBD), vascular dementia (Vas), Parkinson’s disease (PD), tauopathy, frontotemporal dementia, schizophrenia, and bipolar disorder. We show that interindividual variation accounts for a substantial portion of gene expression variation. By comparing transcriptomic variation across diseases, we reveal universal signatures enriched in basic cellular functions such as mRNA processing and protein localization. After discounting these cross-disease signatures, we show stronger genetic and transcriptomic concordance among AD, DLBD, Vas and PD. Furthermore, we characterize transcriptomic variation among different AD phenotypes, distinct from those observed in healthy ageing, revealing a reduction in neuronal abundance in individuals with more severe AD, coupled with an increase in immune and vascular cell populations. Exploring the neuropsychiatric symptoms (NPSs) that frequently accompany AD, we find an increased abundance of deep-layer excitatory neurons associated with a broad range of NPSs. By constructing transcriptome trajectories that capture AD progression, we implicate cell-type-specific responses in the early and late stages of AD. Our disease atlas provides a perspective of the transcriptomic landscape in neurodegenerative and neuropsychiatric disorders, shedding light on shared and distinct processes involving the neurological–immune–vascular systems, and identifying potential targets for therapeutic intervention.
- Open Access
- 23 September 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (10) , 2525-2534
Single-nucleus atlas of cell-type specific genetic regulation in the human brain
Genetic risk variants for common diseases are predominantly located in non-coding regulatory regions and modulate gene expression. Although bulk tissue studies have elucidated shared mechanisms of regulatory and disease-associated genetics, the cellular specificity of these mechanisms remains largely unexplored. Here we present a comprehensive, single-nucleus multi-ancestry atlas of genetic regulation of gene expression in the human prefrontal cortex, comprising 5.6 million nuclei from 1,384 donors of diverse ancestries. Through multi-resolution analyses spanning eight major cell classes and 27 subclasses, we identify genetic regulation for 14,258 genes, with 981 showing cell type-specific regulatory effects at the class level and 857 at the subclass level. Colocalization of genetic variants associated with gene regulation and disease traits uncovers novel cell type-specific genes implicated in Alzheimer’s disease, schizophrenia and other disorders that were not detectable in bulk tissue analyses. Analysis of dynamic genetic regulation at the single-nucleus level identifies 2,073 genes with regulatory effects that vary across developmental trajectories, inferred from a broad age range of donors. We also uncover 1,655 genes with trans -regulatory effects, revealing distal regulation of gene expression. This high-resolution atlas provides insight into the cell type-specific regulatory architecture of the human brain, and offers novel mechanistic targets for understanding the genetic basis of neuropsychiatric and neurodegenerative diseases.
- 23 September 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (10) , 2525-2534
Open AccessSingle-nucleus atlas of cell-type specific genetic regulation in the human brain
Genetic risk variants for common diseases are predominantly located in non-coding regulatory regions and modulate gene expression. Although bulk tissue studies have elucidated shared mechanisms of regulatory and disease-associated genetics, the cellular specificity of these mechanisms remains largely unexplored. Here we present a comprehensive, single-nucleus multi-ancestry atlas of genetic regulation of gene expression in the human prefrontal cortex, comprising 5.6 million nuclei from 1,384 donors of diverse ancestries. Through multi-resolution analyses spanning eight major cell classes and 27 subclasses, we identify genetic regulation for 14,258 genes, with 981 showing cell type-specific regulatory effects at the class level and 857 at the subclass level. Colocalization of genetic variants associated with gene regulation and disease traits uncovers novel cell type-specific genes implicated in Alzheimer’s disease, schizophrenia and other disorders that were not detectable in bulk tissue analyses. Analysis of dynamic genetic regulation at the single-nucleus level identifies 2,073 genes with regulatory effects that vary across developmental trajectories, inferred from a broad age range of donors. We also uncover 1,655 genes with trans -regulatory effects, revealing distal regulation of gene expression. This high-resolution atlas provides insight into the cell type-specific regulatory architecture of the human brain, and offers novel mechanistic targets for understanding the genetic basis of neuropsychiatric and neurodegenerative diseases.
- Open Access
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3682-3694
AI-based characterization of Alzheimer’s disease phenotypes from population-scale single-cell data
The complexity of Alzheimer’s disease (AD) manifests in diverse clinical phenotypes, including cognitive impairment and neuropsychiatric symptoms. However, the etiology of these phenotypes remains elusive. To address this, the PsychAD project generated a population-level single-nucleus RNA sequencing dataset comprising over 6 million nuclei from the prefrontal cortex of >1,000 individual brains, covering a variety of disease phenotypes. Here, leveraging this dataset, we developed a computational framework, called Phenotype Associated Single Cell encoder (PASCode), to score single-cell phenotype associations, and identified ∼1.5 million phenotype-associated cells (PACs) from 584 donors with AD-related phenotypes. PASCode ensembles multiple statistical methods into a graph neural model for robust scoring. Comparing PACs within 27 brain cell subclasses, we prioritized cell subpopulations and their expressed genes for various AD phenotypes. For instance, we identified microglia subpopulations implicated in AD pathology; reactive astrocyte subtypes with altered neuroprotective and neurotoxic gene expression that likely confer cognitive resilience; and enhanced excitatory/inhibitory imbalance and mitochondrial dysfunction in cognitively impaired AD donors. We also identified many PACs for multiple phenotypes, including the astrocytes between AD and depression showing specific gene expression patterns such as inflammation and endoplasmic reticulum stress pathways. These prioritized subpopulations, genes and pathways potentially offer valuable insights for precision diagnostic and therapeutic development. We also validated our findings in external population-scale datasets including AD and major depressive disorder, compiled an AD-phenotypic single-cell atlas and delivered the framework as an open-source tool with pre-trained models and a web application for community use.
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3682-3694
Open AccessAI-based characterization of Alzheimer’s disease phenotypes from population-scale single-cell data
The complexity of Alzheimer’s disease (AD) manifests in diverse clinical phenotypes, including cognitive impairment and neuropsychiatric symptoms. However, the etiology of these phenotypes remains elusive. To address this, the PsychAD project generated a population-level single-nucleus RNA sequencing dataset comprising over 6 million nuclei from the prefrontal cortex of >1,000 individual brains, covering a variety of disease phenotypes. Here, leveraging this dataset, we developed a computational framework, called Phenotype Associated Single Cell encoder (PASCode), to score single-cell phenotype associations, and identified ∼1.5 million phenotype-associated cells (PACs) from 584 donors with AD-related phenotypes. PASCode ensembles multiple statistical methods into a graph neural model for robust scoring. Comparing PACs within 27 brain cell subclasses, we prioritized cell subpopulations and their expressed genes for various AD phenotypes. For instance, we identified microglia subpopulations implicated in AD pathology; reactive astrocyte subtypes with altered neuroprotective and neurotoxic gene expression that likely confer cognitive resilience; and enhanced excitatory/inhibitory imbalance and mitochondrial dysfunction in cognitively impaired AD donors. We also identified many PACs for multiple phenotypes, including the astrocytes between AD and depression showing specific gene expression patterns such as inflammation and endoplasmic reticulum stress pathways. These prioritized subpopulations, genes and pathways potentially offer valuable insights for precision diagnostic and therapeutic development. We also validated our findings in external population-scale datasets including AD and major depressive disorder, compiled an AD-phenotypic single-cell atlas and delivered the framework as an open-source tool with pre-trained models and a web application for community use.
- Open Access
- 23 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9596
Personalized single-cell transcriptomics reveals molecular diversity in Alzheimer’s disease
Alzheimer’s disease (AD) is highly heterogeneous and driven by diverse molecular and cellular mechanisms. Functional genomics investigates these mechanisms from genetic variants to gene expression and regulation. We performed personalized functional genomics analysis on population-scale single-nucleus RNA-seq data, with cross-cohort validation across multiple cohorts comprising over 1900 individual brains, capturing donor-level cell type interactions and gene regulatory networks. Using a knowledge-guided graph neural network, we learned latent representations of each donor’s functional genomics that accurately classified AD phenotypes, identified molecularly defined subpopulations, and traced disease progression trajectories. Our importance scores, derived from graph attentions, identified significant inter-donor differences and prioritized personalized cell type genes and regulatory networks. Finally, we identified gene regulatory QTLs (grQTLs) linking genetic variants to donor-level regulatory changes, providing insights into gene regulatory relationships beyond traditional eQTLs. All results are summarized into a personalized functional genomics atlas for AD, including an open-source framework, iBrainMap, for general use.
- 23 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9596
Open AccessPersonalized single-cell transcriptomics reveals molecular diversity in Alzheimer’s disease
Alzheimer’s disease (AD) is highly heterogeneous and driven by diverse molecular and cellular mechanisms. Functional genomics investigates these mechanisms from genetic variants to gene expression and regulation. We performed personalized functional genomics analysis on population-scale single-nucleus RNA-seq data, with cross-cohort validation across multiple cohorts comprising over 1900 individual brains, capturing donor-level cell type interactions and gene regulatory networks. Using a knowledge-guided graph neural network, we learned latent representations of each donor’s functional genomics that accurately classified AD phenotypes, identified molecularly defined subpopulations, and traced disease progression trajectories. Our importance scores, derived from graph attentions, identified significant inter-donor differences and prioritized personalized cell type genes and regulatory networks. Finally, we identified gene regulatory QTLs (grQTLs) linking genetic variants to donor-level regulatory changes, providing insights into gene regulatory relationships beyond traditional eQTLs. All results are summarized into a personalized functional genomics atlas for AD, including an open-source framework, iBrainMap, for general use.
- Open Access
- 23 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8133) , 1016-1026
Single-nucleus transcriptome-wide association study of human brain disorders
Common brain disorders impose a substantial health burden, but localizing their genetic risk in the brain remains challenging 1 . Although genome-wide association studies have identified numerous loci associated with neuropsychiatric and neurodegenerative disorders, many of these loci lie in non-coding regions that influence gene expression in specific cell types 2–5 . Traditional bulk brain transcriptomic analyses, which often focus on European ancestry cohorts, average over cellular diversity, obscuring genetic risk-related changes in gene expression. Here we use single-nucleus gene expression profiles from the dorsolateral prefrontal cortex in the multi-ancestry PsychAD cohort to develop transcriptomic imputation models of genetically regulated expression across major brain cell types. Applying these models to neuropsychiatric and neurodegenerative disorders reveals thousands of gene–trait associations that are undetectable in bulk tissue analyses and resolves many signals to discrete neuronal, glial and immune cell populations. Cross-ancestry analyses in the Million Veteran Program confirm these associations, reveal pleiotropic effects of cell-type-specific predicted expression and demonstrate that trait-related dysregulation is conserved across ancestries, enabling mapping of causal genes and pathways. Together, these findings provide a cell-type-resolved and ancestry-aware atlas of genetically regulated expression in the human prefrontal cortex and illustrate how single-nucleus transcriptomics can sharpen gene discovery and therapeutic target prioritization for complex brain disorders.
- 23 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8133) , 1016-1026
Open AccessSingle-nucleus transcriptome-wide association study of human brain disorders
Common brain disorders impose a substantial health burden, but localizing their genetic risk in the brain remains challenging 1 . Although genome-wide association studies have identified numerous loci associated with neuropsychiatric and neurodegenerative disorders, many of these loci lie in non-coding regions that influence gene expression in specific cell types 2–5 . Traditional bulk brain transcriptomic analyses, which often focus on European ancestry cohorts, average over cellular diversity, obscuring genetic risk-related changes in gene expression. Here we use single-nucleus gene expression profiles from the dorsolateral prefrontal cortex in the multi-ancestry PsychAD cohort to develop transcriptomic imputation models of genetically regulated expression across major brain cell types. Applying these models to neuropsychiatric and neurodegenerative disorders reveals thousands of gene–trait associations that are undetectable in bulk tissue analyses and resolves many signals to discrete neuronal, glial and immune cell populations. Cross-ancestry analyses in the Million Veteran Program confirm these associations, reveal pleiotropic effects of cell-type-specific predicted expression and demonstrate that trait-related dysregulation is conserved across ancestries, enabling mapping of causal genes and pathways. Together, these findings provide a cell-type-resolved and ancestry-aware atlas of genetically regulated expression in the human prefrontal cortex and illustrate how single-nucleus transcriptomics can sharpen gene discovery and therapeutic target prioritization for complex brain disorders.
- Open Access
- 6 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Downregulated transcription in chromosomal domains of midbrain dopamine neurons linked to schizophrenia
Ventral midbrain dopaminergic neurons are a key cell type for schizophrenia pathophysiology but information about cell type-specific genomic dysregulation in diseased brains is missing. We generated a unique midbrain functional genomics resource with 97 RNA-seq and 34 Hi-C chromosomal contact libraries for Nurr1 + /NeuN+ dopaminergic and their surrounding Nurr1-/NeuN- nuclei, collected from donors diagnosed with schizophrenia (SCZ), bipolar disorder (BD) and compared to neurotypical controls. Among the 954 dopamine neuron genes specifically dysregulated in SCZ, 331 were downregulated, with selective enrichment for risk-associated synaptic plasticity and neuronal connectivity pathways and embedded within dopamine neuron-specific topologically associated chromosomal domains (TAD). Transcript-resolved analysis revealed 2,350 transcripts with altered expression in SCZ dopamine neurons, affecting key susceptibility genes such as the FOXP1, MAPK10, PCM1 and NRXN1. Therefore, genomic dysregulation in the ventral midbrain of subjects diagnosed with SCZ selectively affects dopaminergic neurons, and includes a unilateral association of genetic risk with down-, but not upregulated transcription at the sites of highly organized chromosomal domains harboring neuron-specific genes with complex transcriptional architectures.
- 6 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDownregulated transcription in chromosomal domains of midbrain dopamine neurons linked to schizophrenia
Ventral midbrain dopaminergic neurons are a key cell type for schizophrenia pathophysiology but information about cell type-specific genomic dysregulation in diseased brains is missing. We generated a unique midbrain functional genomics resource with 97 RNA-seq and 34 Hi-C chromosomal contact libraries for Nurr1 + /NeuN+ dopaminergic and their surrounding Nurr1-/NeuN- nuclei, collected from donors diagnosed with schizophrenia (SCZ), bipolar disorder (BD) and compared to neurotypical controls. Among the 954 dopamine neuron genes specifically dysregulated in SCZ, 331 were downregulated, with selective enrichment for risk-associated synaptic plasticity and neuronal connectivity pathways and embedded within dopamine neuron-specific topologically associated chromosomal domains (TAD). Transcript-resolved analysis revealed 2,350 transcripts with altered expression in SCZ dopamine neurons, affecting key susceptibility genes such as the FOXP1, MAPK10, PCM1 and NRXN1. Therefore, genomic dysregulation in the ventral midbrain of subjects diagnosed with SCZ selectively affects dopaminergic neurons, and includes a unilateral association of genetic risk with down-, but not upregulated transcription at the sites of highly organized chromosomal domains harboring neuron-specific genes with complex transcriptional architectures.
- Open Access
- 4 February 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Several novel classes of small regulatory RNAs show widespread changes in schizophrenia and bipolar disorder and extensive linkages to critical brain processes
Transcriptomic studies of post-mortem brain samples in schizophrenia (SCZ) and bipolar disorder (BD) have primarily focused on messenger RNAs (mRNAs) but have given limited attention to small non-coding RNAs (sncRNAs). In this study, we present our analyses of sncRNA profiles from the prefrontal cortex of SCZ and BD cases and controls (53 SCZ cases, 40 BD cases, 77 controls), which we sourced from the Icahn School of Medicine at Mount Sinai and the NIMH Human Brain Collection Core brain banks. Corresponding mRNA-seq data were obtained from the CommonMind Consortium. Using a state-of-the-art pipeline, we mapped reads and determined differentially abundant and co-expressed sncRNAs and mRNAs, adjusting for known and hidden confounders. Across samples, 98% of all sncRNAs comprised miRNA isoforms (60.6%), tRNA-derived fragments (17.8%), rRNA-derived fragments (11.4%), and Y RNA-derived fragments (8.3%). In SCZ, 15% of the identified sncRNAs exhibited significant fold changes (FCs), with many also altered in BD, albeit to a lesser extent. For miRNAs, the FCs correlated strongly with the presence of non-templated nucleotides to their 3′-ends, independently of miRNA identity or locus of origin. Disease- and age-associated sncRNAs and mRNAs revealed accelerated aging in both SCZ and BD. Co-expression analyses also revealed, for the first time, disease-independent associations of many isomiRs, tRFs, rRFs, and yRFs with critical brain processes. These findings suggest complex and previously uncharacterized roles for novel classes of regulatory sncRNAs in synaptic signaling, neurogenesis, memory, behavior, and cognition.
- 4 February 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessSeveral novel classes of small regulatory RNAs show widespread changes in schizophrenia and bipolar disorder and extensive linkages to critical brain processes
Transcriptomic studies of post-mortem brain samples in schizophrenia (SCZ) and bipolar disorder (BD) have primarily focused on messenger RNAs (mRNAs) but have given limited attention to small non-coding RNAs (sncRNAs). In this study, we present our analyses of sncRNA profiles from the prefrontal cortex of SCZ and BD cases and controls (53 SCZ cases, 40 BD cases, 77 controls), which we sourced from the Icahn School of Medicine at Mount Sinai and the NIMH Human Brain Collection Core brain banks. Corresponding mRNA-seq data were obtained from the CommonMind Consortium. Using a state-of-the-art pipeline, we mapped reads and determined differentially abundant and co-expressed sncRNAs and mRNAs, adjusting for known and hidden confounders. Across samples, 98% of all sncRNAs comprised miRNA isoforms (60.6%), tRNA-derived fragments (17.8%), rRNA-derived fragments (11.4%), and Y RNA-derived fragments (8.3%). In SCZ, 15% of the identified sncRNAs exhibited significant fold changes (FCs), with many also altered in BD, albeit to a lesser extent. For miRNAs, the FCs correlated strongly with the presence of non-templated nucleotides to their 3′-ends, independently of miRNA identity or locus of origin. Disease- and age-associated sncRNAs and mRNAs revealed accelerated aging in both SCZ and BD. Co-expression analyses also revealed, for the first time, disease-independent associations of many isomiRs, tRFs, rRFs, and yRFs with critical brain processes. These findings suggest complex and previously uncharacterized roles for novel classes of regulatory sncRNAs in synaptic signaling, neurogenesis, memory, behavior, and cognition.
- Top Cited Papers
- 21 January 2026
- Published by Springer Nature in Nature
- Vol. 651 (8105) , 404-413
Biological insights into schizophrenia from ancestrally diverse populations
Schizophrenia and related psychoses occur in all human populations, with the highest rates of diagnosis among Black individuals and those of mainly African ancestry1. Decades of research have established a highly heritable and polygenic basis for schizophrenia, which is mostly shared across populations2,3,4. However, a recruitment bias towards European cohorts5 has led to discoveries that are poorly generalizable to African populations. This exclusion of the world’s most genetically diverse populations narrows our understanding of disease biology and risks exacerbating health disparities. Here we show that electronic health records linked with genomic data from the Million Veteran Program (MVP)6—a national research programme that looks at the effects of genes, lifestyle, military experiences and exposures on the health and wellness of veterans—enable a comprehensive assessment of schizophrenia genetics in populations of African ancestry in the USA. We identify ancestry-independent associations in African populations and expand the catalogue of implicated regions by more than 100 loci. Through statistical fine-mapping and integrative transcriptomic analyses, we refine disease-associated signals to consensus genes with convergent neurobiological functions. These findings provide a much-needed view of schizophrenia’s genetic architecture in populations of African ancestry, and offer biological insights that both extend previous work and broaden its global relevance.
- 21 January 2026
- Published by Springer Nature in Nature
- Vol. 651 (8105) , 404-413
Top Cited PapersBiological insights into schizophrenia from ancestrally diverse populations
Schizophrenia and related psychoses occur in all human populations, with the highest rates of diagnosis among Black individuals and those of mainly African ancestry1. Decades of research have established a highly heritable and polygenic basis for schizophrenia, which is mostly shared across populations2,3,4. However, a recruitment bias towards European cohorts5 has led to discoveries that are poorly generalizable to African populations. This exclusion of the world’s most genetically diverse populations narrows our understanding of disease biology and risks exacerbating health disparities. Here we show that electronic health records linked with genomic data from the Million Veteran Program (MVP)6—a national research programme that looks at the effects of genes, lifestyle, military experiences and exposures on the health and wellness of veterans—enable a comprehensive assessment of schizophrenia genetics in populations of African ancestry in the USA. We identify ancestry-independent associations in African populations and expand the catalogue of implicated regions by more than 100 loci. Through statistical fine-mapping and integrative transcriptomic analyses, we refine disease-associated signals to consensus genes with convergent neurobiological functions. These findings provide a much-needed view of schizophrenia’s genetic architecture in populations of African ancestry, and offer biological insights that both extend previous work and broaden its global relevance.